Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426345 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
A Phase 3 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
NCT03426345 is a Phase 3 study that was terminated before completion, run by Allergan. The registered enrollment target is 311 participants.
The verdict
NCT03426345, a Phase 3 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
Interventions
- DRUG Placebo
- DRUG Relamorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2018-02-16 |
| Est. Completion | 2020-07-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03426345
The ClinicalTrials.gov registry entry for NCT03426345 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03426345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03426345 about?
NCT03426345 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02". This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
What is the current status of trial NCT03426345?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2018-02-16. Estimated completion is 2020-07-16.
What interventions are being tested in trial NCT03426345?
The interventions under investigation include: Placebo (DRUG), Relamorelin (DRUG).
Who is sponsoring clinical trial NCT03426345?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.